Trial size CADM1 antibodies available in the Antibody Validation Project

Posted by M.Popov on 12th Nov 2020

Trial size CADM1 antibodies available in the Antibody Validation Project

Trial size CADM1 antibodies available in the Antibody Validation Project

Introduction:

The protein synthesised from the CADM1 gene mediates homo- and heterophilic cell-cell adhesion and acts as a tumour suppressor in some cases. Apart from stopping tumour growth, mutations can cause lung cancer, immune diseases and fibrosis. We provide a number of trial sized antibodies, which are suitable for CADM1 research purposes, and to help you make the right decision and find the best suited antibody for you, please find the answers to some of the key topics regarding CADM1 that we have provided in the links below.

What is CADM1?

The protein synthesised from the CADM1 gene mediates homophilic cell-cell adhesion in a Ca(2+)-independent manner, and also mediates heterophilic cell-cell adhesion with CADM3 and NECTIN3 in a Ca(2+)-independent manner. It acts as a tumor suppressor in non-small-cell lung cancer (NSCLC) cells, and an interaction with CRTAM promotes natural killer (NK) cell cytotoxicity and interferon-gamma (IFN-gamma) secretion by CD8+ cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM3 in vivo. This protein may contribute to the less invasive phenotypes of lepidic growth tumor cells, and in mast cells, it may mediate attachment to and promote communication with nerves. It also acts as a synaptic cell adhesion molecule and plays a role in the formation of dendritic spines and in synapse assembly.

Where is CADM1 found?

This protein is usually located in the cell junctions, with small amounts present in intracellular structures. Apart from that, it has membranous expression in most glandular cells, high abundance in central nervous system, testis, islets of Langerhans and basolateral membranes in renal tubules.

What role does CADM1 play in disease?

Mutations or overexpressions of CADM1 lead to lung cancer, immune diseases, including neuromyelitis optica spectrum disorder, and Neurofibromatosis, type 2.

CADM1 antibodies in the Antibody Validation project

St John's Laboratory offers a variety of trial size primary antibodies which target CADM1, which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.

Customer reviewed CADM1 antibodies

ModelNameHostClonalityRatingApplication Tested
STJ96129Anti-TSLC1 antibodyRabbitPolyclonal5IHC

Other CADM1 antibodies available in the Antibody Validation Project

Currently we do not have any CADM1 antibodies available in the AVP.

ModelNameHostClonalityRecommended Applications
STJ22860Anti-CADM1 AntibodyRabbitPolyclonalWB
STJ72327Anti-CADM1 AntibodyGoatPolyclonalELISA,WB
STJ72328Anti-CADM1 AntibodyGoatPolyclonalELISA,WB
STJ72709Anti-CADM1 AntibodyGoatPolyclonalELISA,WB

How does the Antibody Validation Project work?

In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.

The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.

Find out more here.